banner

QIAGEN

  • email
  • twitter
  • linkedin
  • facebook

QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).

Loading company categories...
Homogenization and Bead Tube Methods for Rna Work Part 1: Plants and Animal Tissues & Cells
One of the most efficient ways to extract nucleic acids from a sample is by smashing it against a hard surface repeatedly under high speed until...

Cleaning up Dirty DNA
QIAGEN is cleaning up… DNA and RNA that is. With the addition of the DNeasy and RNeasy PowerClean Pro Cleanup Kits to our portfolio, we thought...

Microbiome Analysis – From Complex Samples to Insight With Confidence
The human microbiome comprises many different varieties of bacteria, viruses, archaea and fungi. These microbes are associated with several...

QIAGEN Digital Insights Friday, July 14, 2023
Open-sourced software comes with a variety of risks. To more effectively advance your research, here’s where to turn instead. “Download… QIAGEN...

QIAGEN Receives U.S. FDA EUA for QIAstat-Dx Test Kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus
• First syndromic testing solution to be deployed in epidemic can differentiate novel coronavirus from 20 other serious respiratory infections •...

QIAGEN Releases QIAstat-Dx Test Kit to the U.S. As First Syndromic Test for Detection of SARS-CoV-2 Coronavirus Under New FDA Policy
• QIAstat-Dx syndromic testing system can differentiate novel coronavirus from 20 other respiratory targets • Requires less than one minute for...

https://media.caboodleai.net/pda/companies/4dc4401d-85c0-490c-910f-9dc6a4ec1f6a.com.png

CA,
United States